Live. Life.
To the Fullest.

Rain Therapeutics is a clinical-stage precision oncology company. Our uncompromised dream is to develop and implement the best precision oncology therapies for patients suffering from cancer. We are rooted in this purpose — extending the quality and length of life for cancer patients where we may be their best hope.

Our Team

The Rain team is a diverse group of individuals who are passionate about cancer care. Interested in joining us? Please contact us at and take a look at our LinkedIn page to learn more about Rain and our company culture.


Rain’s programs focus on specific tumor genetics to meaningfully extend patients’ lives.


Rain’s lead program, RAIN-32 (milademetan), is a small molecule, oral inhibitor of mouse double minute 2 (MDM2). It is being developed in patients with MDM2 amplified or overexpressed cancers.

RAD52 Research Program

Rain’s RAD52 research program is currently in preclinical development. RAD52 plays a central role in the DNA Damage Response (DDR) pathway.


The Rain strategy is aimed at giving patients and their families their lives back. Finding new targeted treatment options for these patients is the essence of our work. Patients are our inspiration.